Nanotechnology, in silico and endocrine-based strategy for delivering paclitaxel and miRNA: Prospects for the therapeutic management of breast cancer

Publication date: Available online 28 December 2019Source: Seminars in Cancer BiologyAuthor(s): Mohammad Azam Ansari, Muthu Thiruvengadam, Zeba Farooqui, Govindaswamy Rajakumar, Qazi Mohammad Sajid Jamal, Mohammad A. Alzohairy, Ahmad Almatroudi, Mohammad N. Alomary, Ill-Min Chung, Ebtesam Abdullah Al-SuhaimiAbstractBreast cancer is one of the most prevalent and reoccurring cancers and the second most common reason of death in women. Despite advancements in therapeutic strategies for breast cancer, early tumor recurrence and metastasis in patients indicate resistance to chemotherapeutic medicines, such as paclitaxel due to the abnormal expression of ER and EGF2 in breast cancer cells. Therefore, the development of alternatives to paclitaxel is urgently needed to overcome challenges involving drug resistance. An increasing number of studies has revealed miRNAs as novel natural alternative substances that play a crucial role in regulating several physiological processes and have a close, adverse association with several diseases, including breast cancer.. Due to the therapeutic potential of miRNA and paclitaxel in cancer research, the current review focuses on the differential roles of various miRNAs in breast cancer development and treatment. miRNA delivery to a specific target site, the development of paclitaxel and miRNA formulations, and nanotechnological strategies for the delivery of nanopaclitaxel in the management of breast cancer are discussed. These strategies involve ...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research